English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/169246
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


BET inhibitors as novel therapeutic agents in breast cancer

AuthorsOcaña, Alberto; Nieto-Jiménez, Cristina; Pandiella, Atanasio
KeywordsBET inhibitors
Breast cancer
Novel targets
Issue Date2017
PublisherImpact Journals
CitationOncotarget 8(41): 71285-71291 (2017)
AbstractTumoral cells not only depend on oncogenic abnormalities to maintain its malignant phenotype but on non-oncogenic vulnerabilities. Targeting epigenomics can modify specific cellular functions required for malignant transformation. The Bromodomain (BRD) family mediates their effect by recruiting proteins of the transcription machinery, recognizing acetylated-lysine residues in nucleosomal histones. Bromodomain and extra-terminal (BET) inhibitors have shown to produce growth inhibition in several tumors through the inhibition of the expression of several transcription factors. In this review we will discuss the current knowledge regarding BET inhibitors in breast cancer. Recent data demonstrates their antiproliferative effect in several cancer subtypes, including the triple negative subtype, or when combined with cell signaling inhibitors. We will also describe options for therapeutic combinations or potential mechanisms of resistance, with special emphasis on their future clinical development.
Publisher version (URL)https://doi.org/10.18632/oncotarget.19744
Identifiersdoi: 10.18632/oncotarget.19744
e-issn: 1949-2553
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
BETcan.pdf1,08 MBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.